Insilico Medicine (HK:3696), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co Limited, a China-based, commercial-stage biopharmaceutical company focused on underserved neurological disorders, announced on Thursday that they are expanding and deepening their AI-driven R&D collaboration.

In the initial phase of the collaboration, launched in March 2025, the companies combined Insilico's generative AI drug discovery platform, Pharma.AI, and drug discovery expertise with Tenacia's specialised scientific insights and proprietary data assets. The programme focused on developing small-molecule inhibitors with strong blood–brain barrier (BBB) permeability for central nervous system (CNS) treatment.

Under the expanded agreement, Insilico and Tenacia plan to leverage generative AI to jointly develop an additional innovative candidate with defined properties for challenging neurological diseases, and advance it to the preclinical candidate (PCC) stage to address differentiated clinical needs. By exploring molecules with distinct profiles, the partners aim to provide a broader and more precise set of therapeutic options for highly challenging nerve system-related conditions, helping mitigate late-stage development risk and improve potential clinical benefit.

The expanded collaboration carries additional potential deal value of up to USD94.75m, with Insilico eligible to receive near-term and milestone payments from Tenacia.